公司股份在联交所买卖适用的股份英文简称将由"INNOVATIVE PHAR"更改为"STARCOIN GROUP"， 而股份中文简称则由"领航医药生物科技"更改为"星太链集团"，自2025年10月3日上午九时正起生效。 公司在联交所的股份代号将维持不变，仍为"399"。 领航医药生物科技(00399)发布公告，根据百慕达公司注册处处长发出的更改名称证书及第二名称证 书，建议将公司的英文名称由"Innovative Pharmaceutical Biotech Limited"更改为"Starcoin Group Limited"，并采纳中文名称"星太链集团有限公司"为公司的第二名称，以取代现有名称"领航医药及生物 科技有限公司"已自2025年9月9日起生效。香港公司注册处处长已于2025年9月23日发出注册非香港公司 变更名称注册证明书，确认公司的新名称已根据香港法例第622章公司条例第XVI部于香港注册登记。 ...

智通财经APP讯，领航医药生物科技(00399)发布公告，根据百慕达公司注册处处长发出的更改名称证书 及第二名称证书，建议将公司的英文名称由"Innovative Pharmaceutical Biotech Limited"更改为"Starcoin Group Limited"，并采纳中文名称"星太链集团有限公司"为公司的第二名称，以取代现有名称"领航医药 及生物科技有限公司"已自2025年9月9日起生效。香港公司注册处处长已于2025年9月23日发出注册非香 港公司变更名称注册证明书，确认公司的新名称已根据香港法例第622章公司条例第XVI部于香港注册 登记。 公司股份在联交所买卖适用的股份英文简称将由"INNOVATIVE PHAR"更改为"STARCOIN GROUP"， 而股份中文简称则由"领航医药生物科技"更改为"星太链集团"，自2025年10月3日上午九时正起生效。 公司在联交所的股份代号将维持不变，仍为"399"。 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責，對其準確 性或完整性亦不發表任何聲明，並明確表示，概不會就因本公告全部或任何部份內容而產生 或因倚賴該等內容而引致之任何損失承擔任何責任。 STARCOIN GROUP LIMITED 星太鏈集團有限公司 除文義另有所指外，本公告所用詞彙與該通函所界定者具有相同涵義。 更改公司名稱 董事會欣然宣佈，根據百慕達公司註冊處處長發出的更改名稱證書及第二名 稱證書，建議將本公司的英文名稱由「Innovative Pharmaceutical Biotech Limited」 更改為「Starcoin Group Limited」，並採納中文名稱「星太鏈集團有限公司」為本 公司的第二名稱，以取代現有名稱「領航醫藥及生物科技有限公司」已自二零 二五年九月九日起生效。香港公司註冊處處長已於二零二五年九月二十三日 發出註冊非香港公司變更名稱註冊證明書，確認本公司的新名稱已根據香港 法例第622章公司條例第XVI部於香港註冊登記。 – 1 – （前稱領航醫藥及生物科技有限公司） （於開曼群島註冊成立並於百慕達存續之有限公司） （股份代號：399） 更改股份 ...

New Stock Activities - Companies currently in the IPO process include Botai Cheliang, Xipuni, and Zijin Gold International [1] - Chery Automobile is at the pricing stage, while Different Group is set for its listing date [1] Earnings Announcements - JBB Builders and Chuangneng Group are scheduled to announce their earnings [1] Shareholder Meetings - Companies holding shareholder meetings include Xinhua Wencuan, Jiajin Investment International, and Everbright Securities [1] - Other companies with scheduled meetings are Jiajin Investment International, Huangdafukong, Liangqing Holdings, Youran Muye, and Jinshi Holdings Group [1] Trading Suspension and Resumption - Changhong Jiahua is set to resume trading [1] Dividend Distribution - Companies with upcoming dividend-related dates include Tian Ge Interactive (ex-dividend date), KLN (dividend payment date), COSCO Shipping Holdings (ex-dividend date), Anta Sports (dividend payment date), and Yisheng Biotechnology (dividend payment date) [1] - Other companies with dividend-related dates include Tai Hing Group (ex-dividend date), Longji Group (dividend payment date), Zhou Li Fu (ex-dividend date), and Junjie Group Holdings (ex-dividend date) [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責，對其準確 性或完整性亦不發表任何聲明，並明確表示，概不會就因本公告全部或任何部份內容而產生 或因倚賴該等內容而引致之任何損失承擔任何責任。 INNOVATIVE PHARMACEUTICAL BIOTECH LIMITED 領航醫藥及生物科技有限公 司 （於開曼群島註冊成立並於百慕達存續之有限公 司） – 1 – 除上文所述者外，認購協議A（經補充協議A及日期為二零二五年八月五日及二 零二五年八月二十六日的延長函件修訂及補充）的所有其他條款及條件將維持 不變，且繼續全面有效及生效。 認購協議B 根據認購協議B（經補充協議B及日期為二零二五年八月五日及二零二五年八月 二十六日的延長函件修訂及補充），倘先決條件未能於二零二五年九月十六日 或認購人B與本公司可能書面協定的其他日期及時間前達成，則認購人B與本 公司於認購協議B（經補充協議B及日期為二零二五年八月五日及二零二五年八 月二十六日的延長函件修訂及補充）項下的所有權利、義務及責任將予停止及 終止，任何一方均不得向另一方提出任何申索，惟先前違反有關條款者則除外。 由於需要額外時間達成認購協 ...

Core Viewpoint - The stock price of Pioneer Pharma Biotechnology (0399.HK) experienced a significant drop of 22.12% to HKD 0.405, marking a nearly two-month low since July 21 [1] Group 1: Company Announcement - Pioneer Pharma announced a placement agreement with China Northern Securities Group, set for August 21, 2025, to issue up to 145 million shares at a placement price of HKD 0.415 per share [1] - The board declared that the placement agreement became invalid as the conditions precedent were not met by September 11, 2025, resulting in the cancellation of the placement [1] Group 2: Financial Implications - The company had previously announced on August 21 that it aimed to raise HKD 58.825 million from the placement of 145 million shares, with the proceeds intended for funding the development of its blockchain technology business [1] - Following the announcement of the placement on August 22, the stock surged by 10.87% [1]

2025年9月9日已获百慕大注册署批准，将领航医药生物科技有限公司改名为：Starcoin Group, Ltd.(星太 链集团有限公司)。 ...

Core Viewpoint - The stock of Pioneer Pharma Biotechnology (00399) has dropped over 19% following the announcement that its placement agreement for up to 145 million new shares, aimed at raising HKD 60.18 million, has lapsed due to unmet conditions by September 11 [1] Group 1: Company Announcement - Pioneer Pharma announced that the placement agreement has become invalid, but the board believes this will not have a significant adverse impact on the company's current operations and financial status [1] - On August 21, the company had previously announced a plan to place shares at HKD 0.415 each, aiming to raise approximately HKD 58.83 million, which was intended for funding the development of blockchain technology [1] Group 2: Market Reaction - As of the report, Pioneer Pharma's stock price fell by 19.23%, trading at HKD 0.42, with a trading volume of HKD 16.28 million [1]

Core Viewpoint - The stock of Pioneer Pharma Biotechnology (00399) has dropped over 19% following the expiration of a share placement agreement aimed at raising HKD 60.18 million, which failed to meet its conditions by the deadline of September 11 [1] Group 1: Stock Performance - As of the report, Pioneer Pharma's stock is down 19.23%, trading at HKD 0.42, with a trading volume of HKD 16.28 million [1] Group 2: Share Placement Agreement - The company announced that the share placement agreement for a maximum of 145 million new shares has become invalid due to unmet conditions [1] - The board believes that the failure of the placement agreement will not have any significant adverse impact on the company's current operations and financial status [1] Group 3: Previous Announcements - On August 21, the company had previously announced a plan to place shares at HKD 0.415 each, aiming to raise approximately HKD 58.83 million, which was intended for funding the development of blockchain technology [1]

Group 1 - The company, Pioneer Pharma Biotech (00399), announced a share placement at a price of HKD 0.415 per share, with a maximum of 145 million shares to be placed [1] - The placement agreement has become invalid as the conditions precedent were not met by September 11, 2025, and the placement will not proceed [1] - All responsibilities under the placement agreement between the placement agent and the company will terminate, and no claims can be made by either party regarding the placement agreement [1]